EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Aztreonam–Avibactam (Emblaveo®) for Carbapenem-Resistant and Metallo-β-Lactamase-Producing Gram-Negative Infections: A Comprehensive Review

Stelian Adrian Ritiu, Norbert Wellmann, Sonia Elena Popovici, Adelina Baloi, Marius Papurica, Daiana Toma, Petru Bucuras, Diana-Maria Mateescu, Maria Alina Lupu, Ovidiu Horea Bedreag

Pharmaceutics · 22.10.2026 · 18 (11) · 1349

DOI: 10.3390/pharmaceutics18111349 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 22.10.2026. Verfasst von Stelian Adrian Ritiu und 9 weiteren Autor:innen. Die Arbeit nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: “Victor Babeș” University of Medicine and Pharmacy, Timișoara, Romania.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metallo-β-lactamase (MBL)-producing Enterobacterales represent a major antimicrobial-resistance threat because MBLs hydrolyse most clinically used β-lactams and are not inhibited by currently approved serine β-lactamase inhibitors. Aztreonam–avibactam (ATM-AVI; Emblaveo®) addresses this therapeutic gap by combining aztreonam, a monobactam that is stable to MBL-mediated hydrolysis, with avibactam, which inhibits many co-produced class A, class C, and selected class D serine β-lactamases. This narrative review synthesizes evidence on ATM-AVI pharmacology, microbiological activity, pharmacokinetics/pharmacodynamics, clinical efficacy, safety, resistance, and regulatory positioning. Large surveillance datasets show high in vitro activity against most MBL-producing Enterobacterales, including many co-producing β-lactamases from multiple Ambler classes. Population pharmacokinetic modelling supports a renal-function-adjusted fixed 3:1 dosing ratio and more reliable joint target attainment than separately administered ceftazidime–avibactam plus aztreonam. In the phase 3 REVISIT trial, clinical cure with ATM-AVI was comparable to meropenem in the overall population; however, few participants had confirmed MBL-positive infections. Direct clinical evidence therefore remains limited, supported by convergent microbiological, pharmacokinetic, and observational data. Regulatory indications differ substantially between the European Union and the United States. ATM-AVI is an important advance for selected MBL-producing and multi-class-co-producing Gram-negative infections, but its long-term value will depend on targeted use, reliable susceptibility testing, continued surveillance, and further trials in the intended target population.

Förderung

  • “Victor Babeș” University of Medicine and Pharmacy, Timișoara, Romania

Zitieren

APA

Ritiu, S. A., Wellmann, N., Popovici, S. E., Baloi, A., Papurica, M., Toma, D., Bucuras, P., Mateescu, D., Lupu, M. A., & Bedreag, O. H. (2026). Aztreonam–Avibactam (Emblaveo®) for Carbapenem-Resistant and Metallo-β-Lactamase-Producing Gram-Negative Infections: A Comprehensive Review. Pharmaceutics, 18(11), 1349. https://doi.org/10.3390/pharmaceutics18111349

Vancouver

Ritiu SA, Wellmann N, Popovici SE, Baloi A, Papurica M, Toma D, et al. Aztreonam–Avibactam (Emblaveo®) for Carbapenem-Resistant and Metallo-β-Lactamase-Producing Gram-Negative Infections: A Comprehensive Review. Pharmaceutics. 2026;18(11):1349. doi:10.3390/pharmaceutics18111349

BibTeX
@article{Ritiu2026,
  author = {Ritiu, Stelian Adrian and Wellmann, Norbert and Popovici, Sonia Elena and Baloi, Adelina and Papurica, Marius and Toma, Daiana and Bucuras, Petru and Mateescu, Diana-Maria and Lupu, Maria Alina and Bedreag, Ovidiu Horea},
  title = {Aztreonam–Avibactam (Emblaveo®) for Carbapenem-Resistant and Metallo-β-Lactamase-Producing Gram-Negative Infections: A Comprehensive Review},
  journal = {Pharmaceutics},
  year = {2026},
  volume = {18},
  number = {11},
  pages = {1349},
  doi = {10.3390/pharmaceutics18111349}
}
Kostenlos starten →